+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Pigmentation Disorders Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026

  • ID: 4620327
  • Report
  • August 2018
  • Region: Global
  • Acute Market Reports
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • ALLERGAN PLC
  • Bayer AG
  • EpiPharm AG
  • Galderma S.A.
  • Obagi Cosmeceuticals LLC
  • Pierre Fabre Laboratories
  • MORE
Pigmentation Disorders Treatment Market - Growth, Future Prospects, Competitive Analysis, 2018 - 2026, the global pigmentation disorders treatment market was valued at US$ 5311.5 Mn in 2017, and is expected to reach US$ 9649.9 Mn by 2026, expanding at a CAGR of 6.9% from 2018 to 2026.

Market Insights
Hyperpigmentation and hypopigmentation are the 2 major disease etiologies of pigmentations disorders. Hyperpigmentation occurs due to the excess secretion of melanin by the skin surface due to defects such as acne, pox and scars achieved due to domestic accidents. Topical creams, chemical peels and microdermabrasion have been used widely over the last 2 decades for treating the skin hyperpigmentation disorders. Vitiligo and albinism are the hypopigmentation disorders that do not have a permanent cure. They cause patients low self-esteem and financial burden imposed by costly photo and laser therapy. The symptoms can be alleviated up to a certain extent by exposure of the skin surface to UVB and UVA phototherapy.

Currently, topical drugs are used throughout the globe for the treatment of hyperpigmentation. Topical creams are available in different formulations and combinations at affordable prices to treat facial dark spots occurring from pox, acne, etc. Microdermabrasion is gaining prominence due to its growing popularity over the counter product (OTC) for the treatment of skin defects such as dark spots and wrinkles.
In the present scenario, melasma is dominating the disease type segment due to its high incidence rate in the Caucasian population, which comprises 55 to 60% of the world population. Hormonal changes, pregnancy and birth control pills are responsible for the occurrence of melasma in 90% women throughout the globe. Vitiligo will be highlighting growth at a rapid pace due to its high prevalence in Negroid and Mongoloid population. Technological advancement in photo and laser therapy has been able to treat vitiligo up to a certain extent.

North America is currently dominating the global market on account of the rising incidence of melasma and post inflammatory hyperpigmentation. Presence of major players engaged in the formulation of topical creams to treat facial hyperpigmentation caused from acne, pox and accidents drive the pigmentation disorders treatment market in North America. Asia Pacific is going to project a remarkable market growth during the forecast period due to key factors such as developing healthcare infrastructure, rise in per capita income and competitive environment created due to proliferation of local players.

The major players engaged in the treatment of pigmentation disorders market are ALLERGAN, BAYER AG, Galderma S.A., EpiPharm AG, Pierre Fabre Laboratories, La Roche Posay, Obagi Cosmeceuticals LLC, RXi Pharmaceuticals, Corporation, SkinCeuticals and Vivier Pharma.

Key Market Movements:
  • Rising incidence of albinism and vitiligo in the negroid and aboriginal population
  • Availability of numerous combinations of topical creams to treat face hyperpigmentation due to acne, pox, accidents etc., in the Caucasian population
  • Supportive regulatory environment will contribute towards the growth of pigmentation disorders market
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • ALLERGAN PLC
  • Bayer AG
  • EpiPharm AG
  • Galderma S.A.
  • Obagi Cosmeceuticals LLC
  • Pierre Fabre Laboratories
  • MORE
Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global Pigmentation Disorders Treatment Market Portraiture
2.2. Global Pigmentation Disorders Treatment Market, by Treatment Type, 2017 (US$ Mn)
2.3. Global Pigmentation Disorders Treatment Market, by Disease Type, 2017 (US$ Mn)
2.4. Global Pigmentation Disorders Treatment Market, by Geography, 2017 (US$ Mn)

Chapter 3. Pigmentation Disorders Treatment Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Pigmentation Disorders Treatment Market, by Key Players, 2017

Chapter 4. Global Pigmentation Disorders Treatment Market, by Treatment Type
4.1. Overview
4.2. Topical Drugs
4.3. Chemical Peels
4.4. Microdermabrasion
4.5. Phototherapy
4.6. Laser Therapy

Chapter 5. Global Pigmentation Disorders Treatment Market, by Disease Type
5.1. Overview
5.2. Melasma
5.3. Albinism
5.4. Vitiligo
5.5. Post-Inflammatory Hyperpigmentation
5.6. Others (Solar Lentigines, Acne Vulgaris, etc.)

Chapter 6. Global Pigmentation Disorders Treatment Market, by Geography
6.1. Overview
6.2. North America Pigmentation Disorders Treatment Market Analysis, 2016 – 2026
6.2.1. North America Pigmentation Disorders Treatment Market, by Treatment Type, 2016 – 2026 (US$ Mn)
6.2.2. North America Pigmentation Disorders Treatment Market, by Disease Type, 2016 – 2026 (US$ Mn)
6.2.3. North America Pigmentation Disorders Treatment Market, by Country, 2016 – 2026 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Pigmentation Disorders Treatment Market Analysis, 2016 – 2026
6.3.1. Europe Pigmentation Disorders Treatment Market, by Treatment Type, 2016 – 2026 (US$ Mn)
6.3.2. Europe Pigmentation Disorders Treatment Market, by Disease Type, 2016 – 2026 (US$ Mn)
6.3.3. Europe Pigmentation Disorders Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific Pigmentation Disorders Treatment Market Analysis, 2016 – 2026
6.4.1. Asia Pacific Pigmentation Disorders Treatment Market, by Treatment Type, 2016 – 2026 (US$ Mn)
6.4.2. Asia Pacific Pigmentation Disorders Treatment Market, by Disease Type, 2016 – 2026 (US$ Mn)
6.4.3. Asia Pacific Pigmentation Disorders Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. China
6.4.3.2. Japan
6.4.3.3. Rest of Asia Pacific
6.5. Latin America Pigmentation Disorders Treatment Market Analysis, 2016 – 2026
6.5.1. Latin America Pigmentation Disorders Treatment Market, by Treatment Type, 2016 – 2026 (US$ Mn)
6.5.2. Latin America Pigmentation Disorders Treatment Market, by Disease Type, 2016 – 2026 (US$ Mn)
6.5.3. Latin America Pigmentation Disorders Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa Pigmentation Disorders Treatment Market Analysis, 2016 – 2026
6.6.1. MEA Pigmentation Disorders Treatment Market, by Treatment Type, 2016 – 2026 (US$ Mn)
6.6.2. MEA Pigmentation Disorders Treatment Market, by Disease Type, 2016 – 2026 (US$ Mn)
6.6.3. MEA Pigmentation Disorders Treatment Market, by Region, 2016 – 2026 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. ALLERGAN PLC
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. Bayer AG
7.3. Galderma S.A.
7.4. EpiPharm AG
7.5. Pierre Fabre Laboratories
7.6. La Roche-Posay Laboratoire Pharmaceutique
7.7. Obagi Cosmeceuticals LLC
7.8. RXi Pharmaceuticals Corporation
7.9. SkinCeuticals, Inc.
7.10. Vivier Pharma, Inc.

List of Figures:
Figure. 1 Pigmentation Disorders Treatment: Research Methodology
Figure. 2 Pigmentation Disorders Treatment: Market Segmentation
Figure. 3 Global Pigmentation Disorders Treatment Market, by Treatment Type, 2017 (US$ Mn)
Figure. 4 Global Pigmentation Disorders Treatment Market, by Disease Type, 2017 (US$ Mn)
Figure. 5 Global Pigmentation Disorders Treatment Market, by Geography, 2017 (US$ Mn)
Figure. 6 Attractive Investment Proposition: by Geography, 2017
Figure. 7 Competitive Analysis: Global Pigmentation Disorders Treatment Market, by Key Players, 2017
Figure. 8 Global Topical Drugs Market for Pigmentation Disorders Treatment, 2016 – 2026 (US$ Mn)
Figure. 9 Global Chemical Peels Market for Pigmentation Disorders Treatment, 2016 – 2026 (US$ Mn)
Figure. 10 Global Microdermabrasion Market for Pigmentation Disorders Treatment, 2016 – 2026 (US$ Mn)
Figure. 11 Global Phototherapy Market for Pigmentation Disorders Treatment, 2016 – 2026 (US$ Mn)
Figure. 12 Global Laser Therapy Market for Pigmentation Disorders Treatment, 2016 – 2026 (US$ Mn)
Figure. 13 Global Melasma Market for Pigmentation Disorders Treatment, 2016 – 2026 (US$ Mn)
Figure. 14 Global Albinism Market for Pigmentation Disorders Treatment, 2016 – 2026 (US$ Mn)
Figure. 15 Global Vitiligo Market for Pigmentation Disorders Treatment, 2016 – 2026 (US$ Mn)
Figure. 16 Global Post-Inflammatory Hyperpigmentation Market for Pigmentation Disorders Treatment, 2016 – 2026 (US$ Mn)
Figure. 17 Global Other Disease Type Market for Pigmentation Disorders Treatment, 2016 – 2026 (US$ Mn)
Figure. 18 U.S. Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)
Figure. 19 Canada Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)
Figure. 20 U.K. Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)
Figure. 21 Germany Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)
Figure. 22 Rest of Europe Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)
Figure. 23 China Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)
Figure. 24 Japan Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)
Figure. 25 Rest of Asia Pacific Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)
Figure. 26 Brazil Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)
Figure. 27 Mexico Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)
Figure. 28 Rest of Latin America Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)
Figure. 29 GCC Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)
Figure. 30 Rest of Middle East and Africa Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)


List of Tables:
Table 1 Global Pigmentation Disorders Treatment Market Portraiture
Table 2 Global Pigmentation Disorders Treatment Market, by Treatment Type, 2016 – 2026 (US$ Mn)
Table 3 Global Pigmentation Disorders Treatment Market, by Disease Type, 2016 – 2026 (US$ Mn)
Table 4 Global Pigmentation Disorders Treatment Market, by Geography, 2016 – 2026 (US$ Mn)
Table 5 North America Pigmentation Disorders Treatment Market, by Treatment Type, 2016 – 2026 (US$ Mn)
Table 6 North America Pigmentation Disorders Treatment Market, by Disease Type, 2016 – 2026 (US$ Mn)
Table 7 North America Pigmentation Disorders Treatment Market, by Country, 2016 – 2026 (US$ Mn)
Table 8 Europe Pigmentation Disorders Treatment Market, by Treatment Type, 2016 – 2026 (US$ Mn)
Table 9 Europe America Pigmentation Disorders Treatment Market, by Disease Type, 2016 – 2026 (US$ Mn)
Table 10 Europe Pigmentation Disorders Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
Table 11 Asia Pacific Pigmentation Disorders Treatment Market, by Treatment Type, 2016 – 2026 (US$ Mn)
Table 12 Asia Pacific Pigmentation Disorders Treatment Market, by Disease Type, 2016 – 2026 (US$ Mn)
Table 13 Asia Pacific Pigmentation Disorders Treatment Market, by Country/Region, 2015 – 2025 (US$ Mn)
Table 14 Latin America Pigmentation Disorders Treatment Market, by Treatment Type, 2016 – 2026 (US$ Mn)
Table 15 Latin America Pigmentation Disorders Treatment Market, by Disease Type, 2016 – 2026 (US$ Mn)
Table 16 Latin America Pigmentation Disorders Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
Table 17 Middle East and Africa Pigmentation Disorders Treatment Market, by Treatment Type, 2016 – 2026 (US$ Mn)
Table 18 Middle East and Africa Pigmentation Disorders Treatment Market, by Disease Type, 2016 – 2026 (US$ Mn)
Table 19 Middle East and Africa Pigmentation Disorders Treatment Market, by Region, 2016 – 2026 (US$ Mn)
Table 20 ALLERGAN PLC: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 21 Bayer AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 22 Galderma S.A.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 23 Epipharm AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 24 Pierre Fabre Laboratories: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 25 La Roche-Posay Laboratorie Pharmaceutique: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 26 Obagi Cosmeceuticals LLC: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 27 RXi Pharmaceuticals Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 28 SkinCeuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 29 Vivier Pharma, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • ALLERGAN PLC
  • Bayer AG
  • Galderma S.A.
  • EpiPharm AG
  • Pierre Fabre Laboratories
  • La Roche-Posay Laboratoire Pharmaceutique
  • Obagi Cosmeceuticals LLC
  • RXi Pharmaceuticals Corporation
  • SkinCeuticals, Inc.
  • Vivier Pharma, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll